“...pleasure and pain, they come and go and don't last... bear them patiently”
—Gita
Pathos InvestmentsEquity Research
Research  ›  Fact Sheets  ›  ZTS

ZOETIS INC.

LISTEDNYSE
SYMBOLZTS
SIC2834
STATE OF INC.–
FISCAL YEAR ENDSDecember 31
CIK1555280

PHARMACEUTICAL PREPARATIONS · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

REVENUES, NET INCOME AND FREE CASH FLOW BY FISCAL YEAR$ billions02468102016201720182019202020212022202320242025RevenuesNet incomeFree cash flowEARNINGS AND DIVIDENDS PER SHARE$ per share0.002.004.006.008.002016201720182019202020212022202320242025EPS dilutedDividends per share

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)Amount%
Total debt9,04273.1
Stockholders' equity3,33126.9
Total capitalization12,373100.0

413,223,602 shares outstanding at 31 July 2026 (cover page of the 10-Q filed 6 August 2026).

LONG-TERM DEBT 12/31/25

($ millions)Amount
Long-term debt, noncurrent9,042
Current maturities0
Short-term borrowings / commercial paper0

CAPITAL STOCK 12/31/25

Common shares authorized6,000,000,000
Common shares issued501,891,243
Treasury shares76,963,708
Par or stated value per share ($)0.01
Outstanding at 7/31/26413,223,602

DIVIDENDS DECLARED/PAID

Fiscal yearPer share $Payout %
20252.0333.7
20241.8032.8
20231.5630.7
20221.3530.1
20211.0725.2

HISTORY AND BUSINESS

HISTORY: State of incorporation not stated in SEC records.

BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 10 Sylvan Way, Parsippany, NJ 07054. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)12/31/2512/31/2412/31/23
Revenues9,4679,2568,544
Cost of revenues2,6662,7192,561
Research and development698686614
Selling, general and administrative2,3782,3182,151
Depreciation and amortization487497491
Interest expense222225239
Income before income taxes3,3603,1332,936
Income taxes687637596
Net income2,6732,4862,344
Earned per share, diluted ($)6.025.475.07
Dividends per share ($)2.031.801.56

CONSOLIDATED BALANCE SHEET

($ millions)12/31/2512/31/24
Receivables, net1,5901,316
Inventories2,4302,306
Total current assets6,7685,986
Property, plant and equipment, net3,6813,391
Goodwill2,7672,724
Total assets15,46714,237
Total current liabilities2,2353,412
Long-term debt9,0425,220
Total liabilities12,1369,467
Stockholders' equity3,3314,770
Total liabilities and equity15,46714,237

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year endedRevenuesOper. incomeNet incomeNet margin %EPS diluted $Div. per share $Oper. cash flowCapital expend.Free cash flowTotal assetsTotal liabilitiesTotal debtStockholders' equityROE %Debt / equity
12/31/259,467–2,67328.26.022.032,9046212,28315,46712,1369,0423,33180.22.71
12/31/249,256–2,48626.95.471.802,9536552,29814,2379,4676,5704,77052.11.38
12/31/238,544–2,34427.45.071.562,3537321,62114,2869,2956,5674,99746.91.31
12/31/228,080–2,11426.24.491.351,9125861,32614,92510,5227,9044,40548.01.79
12/31/217,776–2,03726.24.271.072,2134771,73613,9009,3566,5924,54344.81.45
12/31/206,675–1,63824.53.420.852,1264531,67313,6099,8367,1993,76943.51.91
12/31/196,260–1,50024.03.110.691,7954601,33511,5458,8376,4472,70855.42.38
12/31/185,825–1,42824.52.930.541,7903381,45210,7778,5926,4522,18565.42.95
12/31/175,307–86416.31.750.441,3462241,1228,5866,8004,9531,77048.82.80
12/31/164,888–82116.81.650.397132164977,6496,1504,4681,48755.23.00

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

Zoetis Inc.
CIK 1555280 · EIN 46-0696167

PRINCIPAL OFFICE:

10 Sylvan Way, Parsippany, NJ 07054
Tel.: 973-822-7000

INCORPORATED:

–

INDUSTRY (SEC SIC CODE):

2834 · Pharmaceutical Preparations

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 12 February 2026

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

10/13/268-Kperiod 10/8/26
10/8/268-Kperiod 10/8/26
8/6/268-Kperiod 8/6/26
8/6/2610-Qperiod 6/30/26
8/6/268-Kperiod 8/6/26
5/22/268-Kperiod 5/20/26
5/20/268-Kperiod 5/20/26
5/7/2610-Qperiod 3/31/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/12/26) · 10-K FY2024 (filed 2/13/25) · 10-K FY2023 (filed 2/13/24) · 10-K FY2022 (filed 2/14/23) · 10-K FY2021 (filed 2/15/22) · 10-K FY2020 (filed 2/16/21) · 10-K FY2019 (filed 2/13/20) · 10-K FY2018 (filed 2/14/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.

Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.

Data from SEC filings  ·  Educational only  ·  Not investment advice